S
Samuel K. Martin
Researcher at Kenya Medical Research Institute
Publications - 3
Citations - 488
Samuel K. Martin is an academic researcher from Kenya Medical Research Institute. The author has contributed to research in topics: Vaccination & Blood plasma. The author has an hindex of 3, co-authored 3 publications receiving 462 citations. Previous affiliations of Samuel K. Martin include United States Army Medical Research Unit-Kenya.
Papers
More filters
Journal ArticleDOI
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.
Bernhards Ogutu,Odika J. Apollo,Denise McKinney,Willis Okoth,Joram Siangla,Filip Dubovsky,Kathryn Tucker,John N. Waitumbi,Carter L. Diggs,Janet Wittes,Elissa Malkin,Amanda J. Leach,Lorraine Soisson,Jessica Milman,Lucas Otieno,Carolyn A. Holland,Mark E. Polhemus,Shon Remich,Christian F. Ockenhouse,Joe Cohen,W. Ripley Ballou,Samuel K. Martin,Evelina Angov,V. Ann Stewart,Jeffrey A. Lyon,D. Gray Heppner,Mark R. Withers +26 more
TL;DR: FMP1/AS02 had a good safety profile and was well-tolerated but more reactogenic than the comparator, and is not a promising candidate for further development as a monovalent malaria vaccine.
Journal ArticleDOI
Enzyme-Linked Immunosorbent Assay for Detection of Plasmodium falciparum Histidine-Rich Protein 2 in Blood, Plasma, and Serum
Carolyne M. Kifude,Halli G. Rajasekariah,David J. Sullivan,V. Ann Stewart,Evelina Angov,Samuel K. Martin,Carter L. Diggs,John N. Waitumbi +7 more
TL;DR: Evaluating the use of a commercial PfHRP2 enzyme-linked immunosorbent assay (ELISA) kit with some procedural modifications concludes that Pf HRP2 ELISA using whole-blood and serum samples is a suitable adjunct to microscopy and could ultimately benefit malaria intervention trials.
Journal ArticleDOI
Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children
Mark R. Withers,Mark R. Withers,Denise McKinney,Denise McKinney,Bernhards Ogutu,Bernhards Ogutu,John N. Waitumbi,John N. Waitumbi,Jessica Milman,Odika J. Apollo,Odika J. Apollo,Otieno G Allen,Otieno G Allen,Kathryn Tucker,Lorraine Soisson,Carter L. Diggs,Amanda J. Leach,Janet Wittes,Filip Dubovsky,V. Ann Stewart,Shon Remich,Shon Remich,Joe Cohen,W. Ripley Ballou,Carolyn A. Holland,Jeffrey A. Lyon,Evelina Angov,José A. Stoute,Samuel K. Martin,Samuel K. Martin,D. Gray Heppner +30 more
TL;DR: The FMP1/AS02A vaccine was safe and immunogenic in malaria-exposed 12- to 47-mo-old children and the magnitude of immune response of the 25 and 50 μg doses was superior to that of the 10 μg dose.